ICYMI Fulcrum Therapeutic’s Sickle Cell Disease Treatment On Track for a New Drug Application
source: pixabay.com

ICYMI Fulcrum Therapeutic’s Sickle Cell Disease Treatment On Track for a New Drug Application

As reported in Biospace, Fulcrum Therapeutics has announced it will be submitting an application to the FDA for FTX-6058 as an Investigational New Drug (IND) by the end of 2020…

Continue Reading ICYMI Fulcrum Therapeutic’s Sickle Cell Disease Treatment On Track for a New Drug Application
Close Menu